Loading
JiaRay Group is developing JR8603, a chemotherapy drug attached to a short peptide that is meant to be cut free only inside tumours by an enzyme called legumain. It is in a first trial in people with advanced solid tumours, including stomach and bowel cancer.
JiaRay Group is a family of companies developing tumour-targeted peptide-drug conjugates: JiaRay Therapeutics, Inc., in the San Diego area (Encinitas, California), runs IND-enabling and clinical development; JiaRay Biopharmaceuticals, Ltd., in Jiangsu Province, China, founded in 2013, runs early discovery; and JiaRay Pharmaceuticals, Inc., a Cayman Islands holding company founded in 2016, owns rights outside China. Chief executive Sam Chu founded JiaRay in 2013, according to the company. Its approach uses legumain, an asparaginyl endopeptidase that the company says is overexpressed and active in most solid tumours, on tumour blood vessels and on tumour-associated macrophages, to release a cytotoxic payload from an asparagine-containing peptide linker. The lead candidate JR8603 is a small-molecule peptide-drug conjugate given intravenously; its first-in-human escalation and expansion study in advanced solid tumours, including gastric, oesophagogastric junction and colorectal cancers, is registered as NCT06783569. Its first registered cancer trial, NCT06783569, was posted on ClinicalTrials.gov in January 2025.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/